Literature DB >> 1995228

Right ventricular dysfunction in chronic obstructive pulmonary disease. Evaluation and management.

J R Klinger1, N S Hill.   

Abstract

Cor pulmonale is an important consequence of COPD. Although the incidence is not precisely known, it is seen more frequently in patients with hypoxemia, CO2 retention and severely reduced FEV1. When present, it limits peripheral oxygen delivery, increases shortness of breath, and reduces exercise endurance. It is also associated with higher mortality rates independent of other prognostic variables. Numerous factors may contribute to the development of cor pulmonale in patients with COPD, but its primary cause is chronic alveolar hypoxia resulting in pulmonary vasoconstriction, vascular remodeling and pulmonary hypertension. The physical exam, chest radiograph and ECG may be helpful in detecting the presence of cor pulmonale, but because of anatomic changes that occur in the chest, these tests are often insensitive in patients with COPD. Noninvasive diagnostic techniques utilizing Doppler echocardiography and radionuclide angiography allow for detection of RV dysfunction at an earlier stage and in most cases, preclude the need for right heart catheterization. LTO2 is the only therapy shown to improve survival in patients with COPD. However, statistical proof correlating improvements in pulmonary hemodynamics with increased survival is lacking. Bronchodilators, such as the beta 2 agonists and especially theophylline, may have beneficial effects on pulmonary hemodynamics in addition to their effect on respiratory function and are useful in COPD when RV dysfunction is present. Diuretics and phlebotomy are also useful in improving symptoms in appropriate patients. Vasodilators such as calcium channel blockers and ACE-inhibitors may improve pulmonary hemodynamics acutely, but may lower arterial PO2 by worsening ventilation-perfusion matching or blunt the improvement in pulmonary hemodynamics seen with supplemental oxygen. The long-term benefits of these agents have not been proven and their routine use in patients with cor pulmonale due to COPD cannot be recommended.

Entities:  

Mesh:

Year:  1991        PMID: 1995228     DOI: 10.1378/chest.99.3.715

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  12 in total

Review 1.  Pulmonary hypertension with left-sided heart disease.

Authors:  Marco Guazzi; Ross Arena
Journal:  Nat Rev Cardiol       Date:  2010-10-05       Impact factor: 32.419

Review 2.  Comorbidity of heart failure and chronic obstructive pulmonary disease: more than coincidence.

Authors:  Gülmisal Güder; Frans H Rutten
Journal:  Curr Heart Fail Rep       Date:  2014-09

3.  Perioperative respiratory assessment and management.

Authors:  P D Slinger
Journal:  Can J Anaesth       Date:  1992-05       Impact factor: 5.063

Review 4.  Current management of patients with pulmonary hypertension and right ventricular insufficiency.

Authors:  S R Hankins; E M Horn
Journal:  Curr Cardiol Rep       Date:  2000-05       Impact factor: 2.931

5.  Cardiac troponin I in patients with severe exacerbation of chronic obstructive pulmonary disease.

Authors:  Christophe Baillard; Mohamed Boussarsar; Jean-Philippe Fosse; Emmanuelle Girou; Philippe Le Toumelin; Christophe Cracco; Samir Jaber; Yves Cohen; Laurent Brochard
Journal:  Intensive Care Med       Date:  2003-02-13       Impact factor: 17.440

6.  Acute effects of ANP and BNP on hypoxic pulmonary vasoconstriction in humans.

Authors:  R I Cargill; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1995-12       Impact factor: 4.335

7.  [Right ventricular function and pulmonary hypertension].

Authors:  P Kalischewski; A Kögler; J Schauer
Journal:  Med Klin (Munich)       Date:  1997-01-15

Review 8.  [Right heart failure and cor pulmonale].

Authors:  M Leschke; A Wädlich
Journal:  Internist (Berl)       Date:  2007-09       Impact factor: 0.743

9.  Predictors of mortality in COPD exacerbation cases presenting to the respiratory intensive care unit.

Authors:  Yang Cao; Zhenzhen Xing; Huanyu Long; Yilin Huang; Ping Zeng; Jean-Paul Janssens; Yanfei Guo
Journal:  Respir Res       Date:  2021-03-04

10.  Effect of propofol and etomidate on normoxic and chronically hypoxic pulmonary artery.

Authors:  Nazinigouba Ouédraogo; Boutchi Mounkaïla; Huguette Crevel; Roger Marthan; Etienne Roux
Journal:  BMC Anesthesiol       Date:  2006-03-03       Impact factor: 2.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.